article thumbnail

Patent Dispute Update: Incyte Blocks U.S. Launch of Sun Pharma’s Deuruxolitinib (Leqselvi) for Alopecia Areata

The Dermatology Digest

Incyte filed a lawsuit to try to block the launch of deuruxolitinib, claiming that it infringed on a patent on the use of ruxolitinib (Opzelura), which is approved for atopic dermatitis and vitiligo. Sun Pharma acquired deuruxolitinib when it purchased Concert Pharmaceuticals in March 2023 and received the U.S,

article thumbnail

Case 2: Female, 15 Years Old

Dermatology Times

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.

article thumbnail

Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement

The Dermatology Digest

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We

article thumbnail

Weighing Risks Vs. Benefits of Systemic AD Treatments

The Dermatology Digest

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.,

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.